SABBY MANAGEMENT LLC
Q4 2024 Form 13-F

SPICEWOOD, TEXAS
CIK 0001535610 · CRD 162659 · Exempt reporting adviser
Consolidated report · includes 1 manager since Q3 2024
$76.9M Reported Value Total

SABBY MANAGEMENT, LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $223,496,960, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Exempt Reporting Adviser Discretionary Manager
Private funds (Form ADV)
2 funds · $197.4M gross asset value
Private Equity Fund: $181.5M · Hedge Fund: $15.8M
Source: Form ADV filed 2026-07-08
Reported value
$76.9M
Quarter over quarter
-9.6%
Holdings
16
Top-10 concentration
92.1%

Filing Structure

Reports holdings for

  • Hal Mintz (not a 13F filer in our records) · since Q3 2024 · declared by one filing
  • Mintz Hal · File #028-13502 · Q2 2013 – Q1 2025 · declared by one filing

Key People

Form ADV owners & control persons
Hal David Mintz
PRINCIPAL AND MANAGING MEMBER OF SABBY MANAGEMENT, LLC AND SABBY CAPITAL, LLC
Robert Alan Grundstein
CHIEF COMPLIANCE OFFICER OF SABBY MANAGEMENT, LLC AND SABBY CAPITAL, LLC

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2024 13F record

Q4 2024 13F filing summary

Q4 2024 Form 13F portfolio summary
Period of report December 31, 2024
Filed February 14, 2025
Form 13F-HR
Reported value $76.9M
Positions 16
Change in reported value -58.7%
New positions 12
Exited positions 23
Position turnover 89.7%
Top-10 concentration 92.1%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
16 $110.5M
Q1 2026 13F
Filed May 15, 2026
22 $45.1M
Q4 2025 13F
Filed Feb 17, 2026
25 $69.5M
Q3 2025 13F
Filed Nov 14, 2025
29 $86.4M
Q2 2025 13F
Filed Aug 14, 2025
33 $55.1M
Q1 2025 13F
Filed May 15, 2025
36 $34.0M
Q4 2024 13F
Filed Feb 14, 2025
16 $76.9M
Q3 2024 13F
Filed Nov 14, 2024
27 $186.4M
Q2 2024 13F
Filed Aug 14, 2024
27 $148.7M
Q1 2024 13F
Filed May 15, 2024
43 $173.3M
Q4 2023 13F
Filed Feb 14, 2024
46 $100.0M
Q3 2023 13F
Filed Nov 14, 2023
66 $136.6M
Q2 2023 13F
Filed Aug 14, 2023
68 $122.2M
Q1 2023 13F
Filed May 15, 2023
72 $114.8M
Q4 2022 13F
Filed Feb 14, 2023
89 $114.0M
Q3 2022 13F
Filed Nov 14, 2022
82 $79.3M
Q2 2022 13F
Filed Aug 15, 2022
75 $147.0M
Q1 2022 13F
Filed May 16, 2022
83 $669.7M
Q4 2021 13F
Filed Feb 14, 2022
103 $687.8M
Q3 2021 13F
Filed Nov 15, 2021
93 $739.9M

33 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q4 2024

Largest Q4 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 NYC P ISHARES TR $26.3M 34.19%
2 SPY P SPDR S&P 500 ETF $15.5M 20.12%
3 CORZ P CORE SCIENTIFIC INC $10.6M 13.72%
4 NYC C ISHARES TR $5.2M 6.81%
5 EOSE EOS ENERGY ENTERPRISES $4.1M 5.39%
6 EOSE P EOS ENERGY ENTERPRISES $2.6M 3.33%
7 SPY SPDR S&P 500 ETF $1.9M 2.5%
8 IWM ISHARES TR $1.8M 2.28%
9 VANI VIVANI MEDICAL INC $1.5M 1.98%
10 BTBT BIT DIGITAL INC $1.4M 1.81%
11 SPY C SPDR S&P 500 ETF $1.2M 1.6%
12 BTBT P BIT DIGITAL INC $1.0M 1.33%
13 EOSE C EOS ENERGY ENTERPRISES $843.2K 1.1%
14 RVPH P REVIVA PHARMACEUTCLS HLDGS INC $693.4K 0.9%
15 CKPT P CHECKPOINT THERAPEUTICS INC $577.3K 0.75%
16 CORZ CORE SCIENTIFIC INC $331.0K 0.43%
17 CVM CEL-SCI CORP $284.6K 0.37%
18 VLCN VOLCON INC $238.5K 0.31%
19 LICN LICHEN CHINA LTD $223.3K 0.29%
20 UPC UNIVERSE PHARMACEUTICALS INC $203.3K 0.26%

Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings